Warning Letters
Learn about the types of warning letters on FDA's website.
- Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter.
- To obtain additional available information, contact FDA. Requests to FDA for agency records should be sent to: Food and Drug Administration Division of Freedom of Information (HFI-35), 5630 Fishers Lane, Rockville, MD 20857. Instructions for how to submit an FOI request can be found at How to Make a FOIA Request.
- Frequently requested records may be accessed on the Reading Room page.
| Posted Date | Letter Issue Date | Company Name | Issuing Office | Subject | Response Letter | Closeout Letter | Excerpt |
|---|---|---|---|---|---|---|---|
| US Chem Labs | Center for Drug Evaluation and Research | CDER | CGMP/Finished Pharmaceuticals/Adulterated | … that your website offers “Semaglutide,” “Tirzepatide” and “Thymalin” products for sale in the United States. As described below, your “Semaglutide,” “Tirzepatide” and “Thymalin” products are unapproved new drugs introduced or … Furthermore, your “Semaglutide,” “Tirzepatide” and “Thymalin” products are misbranded drugs under section 502 of … |